Does State Medicaid Cover Alprostadil (Caverject / MUSE)?

What Alprostadil Is and Why Coverage Gets Complicated

Alprostadil is a synthetic prostaglandin E1 (PGE1) that relaxes smooth muscle in penile arteries, producing an erection within 5 to 20 minutes. The FDA approved intracavernosal Caverject in 1995 and the intraurethral MUSE pellet in 1996. Linet and Ogrinc (NEJM, 1996) enrolled 296 men in a crossover trial and showed that MUSE produced erections sufficient for intercourse in 64.9% of administrations versus 18.6% for placebo (P<0.001). [1]

Coverage gets complicated because erectile dysfunction sits in a category that many state legislatures and Medicaid directors have historically classified as "lifestyle" rather than medically necessary. That classification is medically inaccurate, given that ED is strongly associated with cardiovascular disease, diabetes, and depression, but it shapes formulary decisions in a real way. The American Urological Association 2018 guideline update notes that ED "is a harbinger of cardiovascular events" and recommends shared decision-making that includes all FDA-approved therapies, including alprostadil, when first-line oral agents fail. [2]

Because Medicaid is jointly funded by states and the federal government, each state administers its own Preferred Drug List (PDL). The federal Medicaid Drug Rebate Program requires manufacturers to pay rebates but does not force states to cover every drug in every therapeutic category. Alprostadil therefore lands on some state PDLs and not others.

State Medicaid programs that do list alprostadil typically restrict it to ICD-10 code N52 (male erectile dysfunction) and require documentation of an underlying organic cause such as diabetes, radical prostatectomy, or spinal cord injury. [3] Psychogenic ED alone is rarely covered.

Which States Currently Cover Alprostadil on Medicaid

No single federal database publishes a real-time list of state Medicaid PDL decisions for alprostadil. Coverage changes when states renegotiate supplemental rebate agreements, usually on January 1 or July 1 each year. The table below reflects publicly available PDL documents retrieved in Q1 2025.

States with documented formulary coverage (non-preferred or preferred tier) include California (Medi-Cal), New York, Texas, Florida, Pennsylvania, Ohio, Illinois, Michigan, New Jersey, and Washington. States with documented non-coverage or no formulary listing as of Q1 2025 include Georgia, Tennessee, Missouri, and Oklahoma, though prior authorization exceptions remain available in each.

The pattern is not purely geographic. States with larger managed-care carve-outs tend to delegate formulary decisions to Managed Care Organizations (MCOs), which means two beneficiaries in the same state can get different answers depending on their MCO. A 2022 analysis in Health Affairs found that Medicaid MCO formulary variation for specialty drugs within the same state exceeded variation between states for 38% of reviewed drugs. [4] Alprostadil, while not classified as a specialty drug by most states, follows a similar pattern of MCO-level fragmentation.

The practical takeaway: checking your state Medicaid PDL website is only the first step. Patients enrolled in Medicaid managed care must also check their MCO's formulary, which may be more restrictive than the state PDL.

Prior Authorization Criteria for Alprostadil on Medicaid

Prior authorization is required in virtually every state Medicaid program that covers alprostadil at all. The criteria differ in detail but cluster around a consistent set of requirements documented in state coverage policies and supported by AUA guidelines. [2]

Standard criteria seen across most state PA policies include:

Diagnosis documentation. The prescriber must submit a confirmed diagnosis of organic erectile dysfunction under ICD-10 N52.x. Chart notes must establish an organic etiology, typically diabetes mellitus (E11.x), post-prostatectomy status (Z90.79), neurogenic bladder, or hypogonadism (E29.1). A 2021 review in JAMA Internal Medicine found that ED affects approximately 52% of men with type 2 diabetes, reinforcing the medical necessity argument. [5]

Step therapy with PDE5 inhibitors. Nearly all states require a documented trial of at least one phosphodiesterase type 5 inhibitor, most commonly sildenafil 50 mg or tadalafil 5 mg, for a minimum of four to eight weeks. The prescriber must document either a contraindication (concurrent nitrate use, severe hypotension) or treatment failure defined as inadequate erection despite adequate titration. FDA labeling for sildenafil notes absolute contraindication with organic nitrates. [6]

Prescriber type. Several states, including California Medi-Cal and Texas Medicaid, require the prescribing or requesting physician to be a urologist or an endocrinologist. A primary care PA request may be denied on this basis alone, making a urology referral strategically important.

Quantity limits. Most states cap covered units at six injections per month for Caverject or six pellets per month for MUSE, consistent with the maximum recommended dosing frequency in the FDA label. [6]

Submitting complete documentation the first time reduces the PA approval cycle from a typical 14-day window to as few as 3 to 5 days for urgent requests. CMS guidance on Medicaid PA timelines requires a decision within 14 calendar days for standard requests and 72 hours for expedited requests when delay would "seriously jeopardize the enrollee's life or health." [7]

Step Therapy Requirements: PDE5 Inhibitors First

Most state Medicaid programs require trying at least one oral PDE5 inhibitor before approving alprostadil. This reflects standard AUA guideline sequencing: oral agents are first-line, vacuum erection devices and intraurethral or intracavernosal alprostadil are second-line. [2]

The step therapy requirement is waived automatically in several documented situations. Patients with a history of radical prostatectomy or pelvic radiation often have neurogenic ED that does not respond adequately to PDE5 inhibitors. The FDA label for sildenafil notes that efficacy depends on intact nitric oxide signaling, which is disrupted after nerve-sparing prostatectomy. [6] In that context, prescribers should document the surgical history explicitly in the PA request to trigger the step therapy waiver.

Contraindications to PDE5 inhibitors provide a second pathway around step therapy. Co-administration with any nitrate in any form is an absolute contraindication. Patients on alpha-blockers for benign prostatic hyperplasia may also face safety concerns at higher PDE5 inhibitor doses, giving prescribers grounds to argue that alprostadil is the appropriate first-line agent in that subgroup.

A 2020 Cochrane systematic review of alprostadil versus PDE5 inhibitors (12 RCTs, N=1,732) found that intracavernosal alprostadil produced successful intercourse in 60 to 80% of men who had failed oral therapy, with a number needed to treat of approximately 3. [8]

Formulary Tier and Cost Sharing

When alprostadil does appear on a state Medicaid PDL, it almost always lands on a non-preferred brand tier, which carries the highest cost-sharing within Medicaid's structure. Federal law caps Medicaid cost sharing at nominal amounts for most beneficiaries: no more than $4 per prescription for preferred drugs and $8 for non-preferred drugs as of 2024, indexed to the medical CPI. [9]

The manufacturer's list price for Caverject Impulse 10 mcg or 20 mcg averages approximately $600 per month for a supply of six injections. MUSE 500 mcg (six pellets) carries a similar price. [Cash-pay patients therefore face a significant barrier compared to the $4 to $8 Medicaid copay for those who qualify.] The gap matters because some patients with Medicaid incomes may not qualify for manufacturer savings programs.

Generic alprostadil injection (prostaglandin E1) is available from compounding pharmacies at substantially lower cost, typically $80 to $150 per month, but compounded drugs are not covered by Medicaid and carry no FDA approval for the specific formulation. [10]

How to Appeal a Medicaid Denial for Alprostadil

Denials are common, but the appeal process has real teeth. Federal Medicaid law gives beneficiaries the right to a fair hearing before an impartial hearing officer. CMS regulations at 42 CFR §431.220 require states to provide written notice of the denial and information about the hearing process. [11]

Step 1: Request an internal appeal (reconsideration). Most states and MCOs offer a first-level internal appeal within 30 days of the denial notice. Submit additional clinical documentation: operative notes if post-prostatectomy, lab values confirming hypogonadism or diabetes, and a letter from the urologist explaining why PDE5 inhibitors are inadequate or contraindicated.

Step 2: Request a state Medicaid fair hearing. If the internal appeal fails, the beneficiary has the right to a fair hearing administered by the state Medicaid agency. Filing deadlines vary by state but are typically 90 days from the denial notice. At the hearing, the prescriber or a patient advocate can present medical evidence. Studies show that beneficiaries who appear at fair hearings with physician support win approximately 40 to 60% of cases. [12]

Step 3: External independent review. Some states offer a third tier, an external independent medical review, before or after the fair hearing. California Medi-Cal, for example, provides an Independent Medical Review (IMR) through the California Department of Managed Health Care for MCO-administered benefits.

Practical documentation checklist for appeals:

• Diagnosis confirmation with ICD-10 code and date of onset
• Organic etiology evidence (lab results, operative notes, imaging)
• PDE5 inhibitor trial records (drug name, dose, duration, outcome) or contraindication documentation
• Prescribing urologist or endocrinologist letterhead
• Published clinical guideline excerpt from AUA 2018 supporting alprostadil as second-line therapy

The AUA Clinical Practice Guideline on Erectile Dysfunction (2018) states: "Vacuum erection device therapy, intraurethral alprostadil, and intracavernosal injection therapy... are recommended as second-line therapies when first-line treatments fail or are contraindicated." [2] Quoting this language directly in an appeal letter aligns the request with standard of care, which hearing officers must weigh.

Manufacturer Savings Cards and Medicaid Incompatibility

Manufacturer savings cards (also called copay cards or patient assistance cards) for Caverject and MUSE cannot be used when Medicaid is the payer. This is a federal legal restriction, not a manufacturer policy choice. The Anti-Kickback Statute and the federal Medicaid rebate system prohibit drug manufacturers from subsidizing cost sharing for federal healthcare beneficiaries. [13]

Patients who lose Medicaid eligibility may use manufacturer patient assistance programs or independently purchased savings cards during any gap period. Pfizer (Caverject) and Meda Pharmaceuticals (MUSE) both operate patient assistance programs for uninsured or underinsured patients with income below defined thresholds, typically 400% of the federal poverty level.

State pharmaceutical assistance programs (SPAPs), which exist in roughly 15 states, operate outside the federal Medicaid framework and may supplement cost sharing for some Medicaid beneficiaries. New Jersey's PAAD program and Pennsylvania's PACE program are two examples that provide additional drug cost assistance to low-income seniors who also carry Medicaid. Eligibility criteria differ by program.

Caverject vs. MUSE: Does the Formulation Affect Coverage?

Caverject (intracavernosal injection) and MUSE (intraurethral suppository) are both listed as "alprostadil" on most state PDLs, but they may carry different NDC codes and therefore different formulary statuses within the same state's PDL. In practice, most state Medicaid programs that cover one formulation cover the other, but this should be verified at the NDC level before prescribing.

Clinically, the two formulations differ in efficacy and tolerability. The original Linet and Ogrinc NEJM trial of MUSE reported a 64.9% response rate. Intracavernosal Caverject typically shows higher response rates: a phase III trial reported in Journal of Urology (1998) documented successful intercourse in approximately 87% of injections at the optimal dose. [14]

MUSE carries a lower systemic absorption rate and avoids needle use, making it preferable for patients with needle phobia or anticoagulation. Caverject produces more consistent rigidity in men with severe vascular compromise. Prescribers can make a formulary-aware choice: if only one formulation is on the state's preferred tier, prescribing that formulation avoids the non-preferred cost-sharing tier and reduces PA complexity.

Special Populations: Post-Prostatectomy and Diabetic Neuropathy

Two populations warrant specific attention because they have the strongest clinical and regulatory basis for Medicaid coverage of alprostadil.

Post-prostatectomy ED. Radical prostatectomy is the most common cause of medically refractory ED in men under 70. Nerve-sparing surgery preserves cavernous nerve function partially, but a 2019 meta-analysis in European Urology (N=7,924) found that only 54% of men recovered sufficient erectile function at 12 months even with bilateral nerve sparing. [15] Penile rehabilitation protocols using intracavernosal alprostadil starting within four to eight weeks post-surgery are supported by AUA guidance. Coverage requests citing "penile rehabilitation post-radical prostatectomy" carry strong clinical backing.

Diabetic neurogenic ED. The Massachusetts Male Aging Study, which followed 1,709 men aged 40 to 70 for nine years, found that men with treated diabetes had a 28% probability of complete erectile dysfunction versus 9.6% in non-diabetic men. [16] The organic and neurogenic basis of diabetic ED is well established, and the ICD-10 specificity code N52.03 (erectile dysfunction due to diabetes) is available to strengthen PA documentation.

For these two populations, PA approval rates are substantially higher when diagnoses are coded precisely and supported with relevant specialist notes. Vague coding such as "ED" without an organic specifier is the single most common reason for initial PA denial, based on patterns documented in prior authorization transparency reports published by state Medicaid agencies in California, Texas, and New York.

Prescribing Alprostadil: Dose, Administration, and Monitoring

Caverject Impulse is supplied as a dual-chamber syringe in 10 mcg and 20 mcg strengths. The starting dose for most men is 2.5 mcg for neurogenic ED or 5 mcg for vasculogenic ED, titrated upward in-office until a satisfactory erection is achieved with a duration of no more than one hour. [6] The maximum recommended dose is 60 mcg per injection. Patients must be trained in self-injection technique before home use.

MUSE pellets are available in 125, 250, 500, and 1 to 000 mcg strengths. The 500 mcg pellet is the most commonly prescribed starting dose for outpatient use. Onset is typically 5 to 10 minutes. Systemic hypotension can occur, so the first dose should be administered in a monitored setting. [6]

Priapism, defined as an erection lasting more than four hours, is the primary serious adverse event. Patients must be instructed to seek emergency care if erection persists beyond four hours. The published incidence of priapism with intracavernosal alprostadil is approximately 0.4% per injection in clinical trials. [1] Penile pain at the injection or suppository site is more common, affecting approximately 11% of men in the MUSE key trial. [1]

Monitoring after initiating alprostadil should include assessment at 3 months for injection technique, penile fibrosis (Peyronie's-like plaques can develop with chronic injection), and dose optimization. The FDA label recommends limiting injection to no more than three times per week with at least a 24-hour interval between uses. [6]

A 2023 systematic review in BJU International covering 18 randomized controlled trials confirmed that intracavernosal alprostadil remains one of the most effective pharmacological treatments for ED refractory to oral therapy, with response rates consistently between 60 and 85% across etiologies. [17]

Patients whose Medicaid coverage is confirmed should receive written instructions that include: the approved NDC number to present at the pharmacy, the quantity limit per 30-day supply, the PA reference number, and the PA expiration date. PA approvals for alprostadil typically run 12 months, after which re-authorization requires updated clinical documentation confirming continued organic etiology and treatment response.